JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on Kyverna Therapeutics (NASDAQ:KYTX) but lowers the price target from $39 to $33.

July 31, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Brian Cheng maintains an Overweight rating on Kyverna Therapeutics but lowers the price target from $39 to $33.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns about future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100